Shares of Amgen Inc. (NASDAQ:AMGN) have been assigned an average recommendation of “Buy” from the twenty-seven analysts that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $186.10.

A number of research analysts have recently issued reports on AMGN shares. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $189.00 price target on shares of Amgen in a report on Friday, June 30th. Cowen and Company reiterated an “outperform” rating and issued a $209.00 price target on shares of Amgen in a report on Wednesday, April 19th. BidaskClub upgraded Amgen from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 23rd. Jefferies Group LLC restated a “hold” rating and set a $180.00 target price on shares of Amgen in a research note on Monday, May 22nd. Finally, Credit Suisse Group AG set a $177.00 target price on Amgen and gave the stock a “hold” rating in a research note on Friday, July 14th.

TRADEMARK VIOLATION NOTICE: “Amgen Inc. (AMGN) Receives Average Recommendation of “Buy” from Analysts” was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.watchlistnews.com/amgen-inc-amgn-receives-average-recommendation-of-buy-from-analysts/1492673.html.

Shares of Amgen (NASDAQ:AMGN) traded down 0.28% on Tuesday, hitting $170.04. The stock had a trading volume of 1,956,277 shares. Amgen has a 12 month low of $133.64 and a 12 month high of $184.21. The company’s 50 day moving average price is $174.35 and its 200-day moving average price is $167.93. The company has a market cap of $124.07 billion, a P/E ratio of 15.49 and a beta of 1.35.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.67 billion. During the same period last year, the business posted $2.84 EPS. The business’s revenue was up 2.1% compared to the same quarter last year. On average, analysts expect that Amgen will post $12.57 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Thursday, August 17th will be issued a $1.15 dividend. The ex-dividend date is Tuesday, August 15th. This represents a $4.60 annualized dividend and a dividend yield of 2.71%. Amgen’s dividend payout ratio (DPR) is presently 41.93%.

In other news, SVP Cynthia M. Patton sold 2,922 shares of the business’s stock in a transaction dated Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total value of $451,156.80. Following the completion of the transaction, the senior vice president now owns 24,214 shares of the company’s stock, valued at approximately $3,738,641.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.20% of the company’s stock.

Several institutional investors have recently modified their holdings of the stock. Camelot Portfolios LLC acquired a new position in Amgen during the first quarter worth $1,429,000. Private Asset Management Inc. boosted its position in Amgen by 117.8% in the first quarter. Private Asset Management Inc. now owns 3,591 shares of the medical research company’s stock worth $589,000 after buying an additional 1,942 shares during the last quarter. Cadence Bank NA boosted its position in Amgen by 6.2% in the first quarter. Cadence Bank NA now owns 3,376 shares of the medical research company’s stock worth $554,000 after buying an additional 197 shares during the last quarter. Stillwater Capital Advisors LLC acquired a new position in Amgen during the first quarter worth $202,000. Finally, Kornitzer Capital Management Inc. KS boosted its position in Amgen by 70.6% in the first quarter. Kornitzer Capital Management Inc. KS now owns 38,865 shares of the medical research company’s stock worth $6,377,000 after buying an additional 16,080 shares during the last quarter. 79.12% of the stock is owned by institutional investors and hedge funds.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.